Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞州雷德伍德城，2024年11月20日（GLOBE NEWSWIRE）——Adverum Biotechnologies, Inc.（納斯達克股票代碼：ADVM）今天宣佈，根據Adverum的2017年激勵計劃，Adverum董事會薪酬委員會向新員工發放了一項由不合格股票期權組成的激勵性獎勵，用於向新員工購買55,000股普通股。根據納斯達克上市規則5635（c）（4），Adverum董事會薪酬委員會批准該獎勵作爲新員工就業的激勵材料。
The stock option has an exercise price per share equal to $6.86, Adverum's closing trading price on November 15, 2024, and will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and 1/48th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. The award is subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
股票期權的每股行使價等於6.86美元，即Adverum在2024年11月15日的收盤交易價格，將在四年內歸屬，25％的標的股票在適用的歸屬開始日一週年之際歸屬，標的股份餘額的1/48將在36個月內每月歸屬，但要視新員工在適用的歸屬日期之前與Adverum的持續服務關係而定。該獎勵受Adverum2017年激勵計劃的條款和條件以及涵蓋該補助金的適用獎勵協議的條款和條件的約束。
About Adverum Biotechnologies
關於 Adverum 生物技術
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
Adverum Biotechnologies（納斯達克股票代碼：ADVM）是一家處於臨床階段的公司，旨在將基因療法確立爲高度流行的眼部疾病的新護理標準，以開發恢復視力和預防失明的功能性療法。利用其專有的玻璃體內注射（IVT）平台的功能，Adverum正在開發耐用的單一給藥療法，該療法旨在在醫生辦公室交付，從而無需頻繁進行眼部注射來治療這些疾病。Adverum正在評估其新的候選基因療法ixoberogene soroparvovec（ixo-vec，前身爲advm-022），這是一種針對新生血管或溼性年齡相關性黃斑變性患者的一次性體外靜脈注射劑。此外，通過克服與當前使人衰弱的眼部疾病治療模式相關的挑戰，Adverum渴望改變護理標準，保持視力，並在全球範圍內產生深遠的社會影響。欲了解更多信息，請訪問。
Inquiries:
查詢：
Adverum Investor Relations
Adverum 投資者關係
Email: ir@adverum.com
電子郵件：ir@adverum.com
